- United Kingdom
- /
- Life Sciences
- /
- AIM:FAB
Fusion Antibodies Full Year 2024 Earnings: EPS Misses Expectations
Fusion Antibodies (LON:FAB) Full Year 2024 Results
Key Financial Results
- Revenue: UK£1.14m (down 61% from FY 2023).
- Net loss: UK£2.23m (loss narrowed by 14% from FY 2023).
- UK£0.039 loss per share (improved from UK£0.10 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Fusion Antibodies EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%.
The company's shares are up 6.5% from a week ago.
Risk Analysis
Be aware that Fusion Antibodies is showing 6 warning signs in our investment analysis and 4 of those are a bit unpleasant...
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:FAB
Fusion Antibodies
A contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.
Medium-low with mediocre balance sheet.